Abstract
Inflammation is an important process and an underlying mechanism involved in atherogenesis as well as the clinical manifestations following coronary artery disease (CAD). Evidence suggests that chronic heart failure (CHF) is associated with an increased inflammatory process. Pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa), interleukin-6 (IL-6), interleukin-1 (IL-1) and adhesion molecules are elevated in states of CHF and are related to long term prognosis. Statins are among the most effective compounds reducing morbidity and mortality in patients with, or at increased risk of, CAD. Efficacy and safety of statin treatment has not been validated in patients with CHF. Several studies have reported that statins could be beneficial in patients with CHF. In addition, the beneficial effects of statins have been largely attributed to their anti-inflammatory properties. However, recent randomized, double-blind, placebo-controlled trials reported that statins did not affect clinical outcomes in patients with CHF of any cause. These data support the notion that current immunomodulation approaches in heart failure are not successful. Thus, more large scale clinical trials are required to evaluate the impact of statins on immune imbalance and its restoration in patients with CHF.
Keywords: Heart failure, statins, anti-inflammatory, immunomodulation
Current Vascular Pharmacology
Title: The Failure of Immunomodulation Therapy in Heart Failure: Does the Statins “Paradigm” Prove the Rule?
Volume: 8 Issue: 1
Author(s): Dimitris Tousoulis, Nikolaos Papageorgiou, Alexandros Briasoulis, Charalambos Antoniades and Christodoulos Stefanadis
Affiliation:
Keywords: Heart failure, statins, anti-inflammatory, immunomodulation
Abstract: Inflammation is an important process and an underlying mechanism involved in atherogenesis as well as the clinical manifestations following coronary artery disease (CAD). Evidence suggests that chronic heart failure (CHF) is associated with an increased inflammatory process. Pro-inflammatory cytokines such as tumor necrosis factor alpha (TNFa), interleukin-6 (IL-6), interleukin-1 (IL-1) and adhesion molecules are elevated in states of CHF and are related to long term prognosis. Statins are among the most effective compounds reducing morbidity and mortality in patients with, or at increased risk of, CAD. Efficacy and safety of statin treatment has not been validated in patients with CHF. Several studies have reported that statins could be beneficial in patients with CHF. In addition, the beneficial effects of statins have been largely attributed to their anti-inflammatory properties. However, recent randomized, double-blind, placebo-controlled trials reported that statins did not affect clinical outcomes in patients with CHF of any cause. These data support the notion that current immunomodulation approaches in heart failure are not successful. Thus, more large scale clinical trials are required to evaluate the impact of statins on immune imbalance and its restoration in patients with CHF.
Export Options
About this article
Cite this article as:
Tousoulis Dimitris, Papageorgiou Nikolaos, Briasoulis Alexandros, Antoniades Charalambos and Stefanadis Christodoulos, The Failure of Immunomodulation Therapy in Heart Failure: Does the Statins “Paradigm” Prove the Rule?, Current Vascular Pharmacology 2010; 8 (1) . https://dx.doi.org/10.2174/157016110790226589
DOI https://dx.doi.org/10.2174/157016110790226589 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stiff Left Atrial Syndrome; Prospects and Possibilities. Retrospective Analysis and Review of the Literature
Current Hypertension Reviews Nitric Oxide and Protection against Cardiac Ischemia
Current Pharmaceutical Design Editorial (Thematic Issue: Experimental Pharmacological Targets for the Treatment of Cardiac Arrhythmias: Beyond the Vaughn-Williams Classification)
Current Medicinal Chemistry Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints
Current Pharmaceutical Design Fighting Tumor Cell Survival: Advances in the Design and Evaluation of Pim Inhibitors
Current Medicinal Chemistry DNA Methylation: An Epigenetic Insight into Type 2 Diabetes Mellitus
Current Pharmaceutical Design The Beneficial Role of Vitamin D in Human Immunodeficiency Virus Infection
Current HIV Research Mapping the High Throughput SEREX Technology Screening for Novel Tumor Antigens
Combinatorial Chemistry & High Throughput Screening Mechanisms of Fetal and Neonatal Renal Impairment by Pharmacologic Inhibition of Angiotensin
Current Medicinal Chemistry Interference of Metals and Medications with the Detection of Lipid Peroxidation in Humans by Photometric TBARS Assay
Current Analytical Chemistry A Practical Approach to Diagnosis and Treatment of Symptomatic Thromboembolic Events in Children with Acute Lymphoblastic Leukemia: Recommendations of the “Coagulation Defects” AIEOP Working Group
Recent Patents on Cardiovascular Drug Discovery Adonis sp., Convallaria sp., Strophanthus sp., Thevetia sp., and Leonurus sp. - Cardiotonic Plants with Known Traditional Use and a Few Preclinical and Clinical Studies
Current Pharmaceutical Design CYP24A1 as a Potential Target for Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Gene Therapy in Lung Transplantation
Current Gene Therapy Cardiac Stem Cell-Based Myocardial Regeneration: Towards a Translational Approach
Cardiovascular & Hematological Agents in Medicinal Chemistry Beneficial Effects of Statins on Endothelial Dysfunction and Vascular Stiffness
Current Vascular Pharmacology Microvascular Obstruction After Primary Percutaneous Coronary Intervention: Pathogenesis, Diagnosis and Prognostic Significance
Current Vascular Pharmacology FDG-PET Scan in Sarcoidosis: Clinical and Imaging Indications
Current Medical Imaging Role of Nanomedicine in Hepatic Targeting- Deciphering Strategies with Molecular Insights and Preclinical Prospects
Drug Delivery Letters Clinical Pharmacokinetics of Systemically Administered Antimycotics
Current Clinical Pharmacology